Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

BACKGROUND Sarcoidosis is a disorder of unknown aetiology. Most patients have steroid-responsive disease, but side effects and steroid resistance may necessitate alternative treatments. Endothelin has in-vitro fibrogenic activity and the endothelin system is activated in sarcoidosis....

Full description

Bibliographic Details
Main Authors: Katrin E. Hostettler, Florent Baty, Rebekka Kleiner, Lilian Junker, Michael Tamm, Martin H. Brutsche
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2018-10-01
Series:Swiss Medical Weekly
Subjects:
Lung
Treatment
anti-fibrotic
Endothelin-1
Online Access:https://www.smw.ch/index.php/smw/article/view/2531

Similar Items

Similar Items